ALK y ROS-1 en CNMP: Presente y Futuro - page 24

FUTURE

First-line

Phase 3 studies of novel ALK inhibitors in NSCLC

* ALEX: Alectinib vs Crizotinib; ALTA: Brigatinib vs. crizotinib

* eXalt3: Ensartinib vs. Crizotinib

1L 2L

Next gen ALK TKI

Sequence

Crizotinib

Next gen ALK TKI

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,14,15,16,17,18,19,20,21,22,23 25,26,27,28,29,30,31,32,33